Mark Coleman Sells 6,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $233.46, for a total value of $1,400,760.00. Following the transaction, the director owned 41,140 shares of the company’s stock, valued at approximately $9,604,544.40. This trade represents a 12.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mark Coleman also recently made the following trade(s):

• On Tuesday, June 2nd, Mark Coleman sold 5,537 shares of Axsome Therapeutics stock. The stock was sold at an average price of $223.39, for a total value of $1,236,910.43.
• On Monday, June 1st, Mark Coleman sold 6,000 shares of Axsome Therapeutics stock. The stock was sold at an average price of $230.30, for a total value of $1,381,800.00.

Axsome Therapeutics Stock Performance

AXSM opened at $233.31 on Thursday. The stock has a market cap of $12.01 billion, a PE ratio of -62.55 and a beta of 0.61. The company has a current ratio of 1.39, a quick ratio of 1.32 and a debt-to-equity ratio of 2.27. Axsome Therapeutics, Inc. has a 1 year low of $96.09 and a 1 year high of $238.56. The stock’s 50 day simple moving average is $199.79 and its 200-day simple moving average is $177.40.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The firm had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The business’s revenue was up 57.4% compared to the same quarter last year. Sell-side analysts forecast that Axsome Therapeutics, Inc. will post -2.14 EPS for the current year.

Institutional Trading of Axsome Therapeutics

Large investors have recently bought and sold shares of the stock. Birchview Capital LP lifted its stake in shares of Axsome Therapeutics by 1.0% during the fourth quarter. Birchview Capital LP now owns 6,061 shares of the company’s stock valued at $1,107,000 after acquiring an additional 61 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Axsome Therapeutics by 3.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,921 shares of the company’s stock valued at $351,000 after acquiring an additional 65 shares during the period. Xponance LLC lifted its stake in shares of Axsome Therapeutics by 2.4% during the fourth quarter. Xponance LLC now owns 3,265 shares of the company’s stock valued at $596,000 after acquiring an additional 76 shares during the period. Assetmark Inc. lifted its stake in shares of Axsome Therapeutics by 7.2% during the first quarter. Assetmark Inc. now owns 1,182 shares of the company’s stock valued at $200,000 after acquiring an additional 79 shares during the period. Finally, Allworth Financial LP lifted its stake in shares of Axsome Therapeutics by 6.6% during the third quarter. Allworth Financial LP now owns 1,442 shares of the company’s stock valued at $175,000 after acquiring an additional 89 shares during the period. 81.49% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft set a $280.00 price objective on Axsome Therapeutics in a research report on Tuesday, May 5th. HC Wainwright boosted their price objective on Axsome Therapeutics from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Cantor Fitzgerald restated an “overweight” rating and set a $272.00 price objective on shares of Axsome Therapeutics in a research report on Monday, May 4th. Oppenheimer set a $280.00 price objective on Axsome Therapeutics in a research report on Monday, May 4th. Finally, Truist Financial upgraded Axsome Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $251.26.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.